Fluoxetine Use for Very Young Children with Major Depression Disorder: A Pilot Randomized Clinical Trial

Area of Science:

• Pediatric Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major depressive disorder (MDD) presents a significant global health challenge.
• Fluoxetine is approved for MDD in individuals over six, but its efficacy in younger children remains unexplored.
• This pilot study investigates fluoxetine's use in 4-6-year-old children with MDD.

Purpose of the Study:

• To evaluate the safety and efficacy of fluoxetine in treating major depressive disorder (MDD) in very young children aged 4-6 years.
• To compare fluoxetine's effects against a placebo in this pediatric population.
• To assess the incidence of side effects associated with fluoxetine treatment in young children.

Main Methods:

• A double-blind, randomized clinical trial involving 40 children aged 4-6 with MDD.
• Participants received either 0.7 mg/kg daily fluoxetine (n=20) or a placebo (n=20) for 60 days.
• The Preschool Feelings Checklist-Scale (PFC-S) and Antidepressant Side Effect Checklist (ASEC) were used for assessments.

Main Results:

• Fluoxetine treatment led to a significant decrease in PFC-S scores (P < 0.001), unlike the placebo group (P = 0.317).
• A significant difference in PFC-S scores was observed between the fluoxetine and placebo groups (P < 0.001) at both 30 and 60 days.
• No fluoxetine-related side effects were reported by any participants.

Conclusions:

• Fluoxetine appears to be a safe and effective treatment for depression in very young children (4-6 years).
• The findings suggest potential for fluoxetine in managing early-onset pediatric depression.
• Further research is recommended due to limited data and the need for conclusive evidence.